Last reviewed · How we verify
glucose solution only
At a glance
| Generic name | glucose solution only |
|---|---|
| Also known as | Group 2 |
| Sponsor | HaEmek Medical Center, Israel |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa) (PHASE3)
- Comparison of Hyaluronic Acid, Injectable Platelet-Rich Fibrin, and Prolotherapy in TMJ Arthrocentesis (NA)
- Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers (PHASE1)
- Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU) (PHASE2)
- Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause (PHASE1, PHASE2)
- Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (PHASE3)
- Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection (PHASE2)
- Add-on Intravenous Immunoglobulins in Early Myositis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- glucose solution only CI brief — competitive landscape report
- glucose solution only updates RSS · CI watch RSS
- HaEmek Medical Center, Israel portfolio CI